News
TLSA
0.5699
-6.65%
-0.0406
Weekly Report: what happened at TLSA last week (1109-1113)?
Weekly Report · 4h ago
Tiziana Life Sciences Ltd to Present at the Jefferies Global Healthcare Conference 2026
NASDAQ · 3d ago
Tiziana Life Sciences Announces Jefferies Healthcare Conference Presentation
TipRanks · 4d ago
BTIG Sticks to Their Buy Rating for Tiziana Life Sciences (TLSA)
TipRanks · 6d ago
Tiziana Life Sciences Ltd Highlights Positive Phase 2a INFORM-MS Topline Results and 12-Week Clinical Benefits of Intranasal Foralumab
NASDAQ · 6d ago
Tiziana Life Sciences Highlights INFORM-MS Phase 2a Results in KOL Call Update
TipRanks · 6d ago
Tiziana Life Sciences Highlights Phase 2a INFORM-MS Success For Intranasal Foralumab, Showing Reduced Neuroinflammation And Improved Fatigue In Secondary Progressive MS
Benzinga · 6d ago
Tiziana Life Sciences Ltd to Present at BIO-Europe 2026 and Host KOL Webcast
NASDAQ · 6d ago
Tiziana Life Sciences Presents Foralumab Program at BIO-Europe 2026
TipRanks · 11/09 12:33
Weekly Report: what happened at TLSA last week (1102-1106)?
Weekly Report · 11/09 09:34
Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split
NASDAQ · 11/06 14:54
Tiziana Life Sciences Ltd Announces Positive Phase 2a INFORM-MS Topline Results
NASDAQ · 11/06 06:38
Tiziana Life Sciences Reports Positive Phase 2a INFORM-MS Results for Intranasal Foralumab
TipRanks · 11/05 19:47
Tiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis Trial
NASDAQ · 11/03 07:56
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Tiziana Life Sciences (TLSA) and Verastem (VSTM)
TipRanks · 11/03 02:41
Encouraging Phase 2a INFORM-MS Results Support Foralumab; $7 Price Target Reaffirmed
TipRanks · 11/03 02:40
Tiziana falters following mid-stage results for multiple sclerosis asset
Seeking Alpha · 11/02 20:13
Tiziana Reports Positive Imaging And Fatigue Data For Foralumab
NASDAQ · 11/02 16:06
Tiziana Reports Positive Phase 2a Foralumab Results in Progressive MS
TipRanks · 11/02 12:25
Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints
Benzinga · 11/02 12:11
More
Webull provides a variety of real-time TLSA stock news. You can receive the latest news about Tiziana Life Sciences Ltd Com through multiple platforms. This information may help you make smarter investment decisions.
About TLSA
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.